(Total Views: 615)
Posted On: 07/30/2020 7:01:23 PM
Post# of 150989
Re: invisioner #46208
I believe Regeneron included SAEs as endpoint in trial design. Can’t go back and add an endpoint if you’re not a BP.
Cytodyn will meets its endpoints, just slower for analysis than a/c dead/alive.
I didn’t follow manufacturing update as closely, I believe production this year decreased as manufacturing capacity given to approved drugs.
Presumably capacity will ramp quickly with EUA/approval and government assistance.
Cytodyn will meets its endpoints, just slower for analysis than a/c dead/alive.
I didn’t follow manufacturing update as closely, I believe production this year decreased as manufacturing capacity given to approved drugs.
Presumably capacity will ramp quickly with EUA/approval and government assistance.
(1)
(0)Scroll down for more posts ▼
